Q0164 - Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
5 MG |
0.296 |
- |
- |
- |
- |
- |
- |
|
|
Q0166 - Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen |
1 MG |
1.463 |
- |
- |
- |
- |
- |
- |
|
|
Q0167 - Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
2.5 MG |
0.803 |
- |
- |
- |
- |
- |
- |
|
|
Q2043 - Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion |
Per infusion (minimum 50 million cells) |
49649.408 |
- |
- |
- |
- |
- |
- |
|
|
Q2050 - Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg |
10 MG |
298.802 |
- |
- |
- |
- |
- |
- |
|
|
Q3027 - Injection, interferon beta-1a, 1 mcg for intramuscular use |
1 MCG |
54.417 |
- |
- |
- |
- |
- |
- |
|
|
Q4074 - Iloprost, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 20 micrograms |
UP TO 20 MCG |
140.088 |
- |
- |
- |
- |
- |
- |
|
|
Q4081 - Injection, epoetin alfa, 100 units (for esrd on dialysis) |
100 UNITS |
0.882 |
- |
- |
- |
- |
- |
- |
|
|
Q4101 - Apligraf, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
30.456 |
- |
- |
- |
- |
- |
- |
|
|
Q4102 - Oasis wound matrix, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
9.563 |
- |
- |
- |
- |
- |
- |
|
|
Q4106 - Dermagraft, per square centimeter |
1 SQ CM |
31.858 |
- |
- |
- |
- |
- |
- |
|
|
Q4110 - Primatrix, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
42.33 |
- |
- |
- |
- |
- |
- |
|
|
Q4111 - Gammagraft, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
7.02 |
- |
- |
- |
- |
- |
- |
|
|
Q4121 - Theraskin, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
43.449 |
- |
- |
- |
- |
- |
- |
|
|
Q4132 - Grafix core and grafixpl core, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
116.594 |
- |
- |
- |
- |
- |
- |
|
|
Q4133 - Grafix prime, grafixpl prime, stravix and stravixpl, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
135.234 |
- |
- |
- |
- |
- |
- |
|
|
Q4137 - Amnioexcel, amnioexcel plus or biodexcel, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
86.589 |
- |
- |
- |
- |
- |
- |
|
|
Q4145 - Epifix, injectable, 1 mg |
1 MG |
18.662 |
- |
- |
- |
- |
- |
- |
|
|
Q4151 - Amnioband or guardian, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
126.011 |
- |
- |
- |
- |
- |
- |
|
|
Q4154 - Biovance, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
110.822 |
- |
- |
- |
- |
- |
- |
|
|
Q4160 - Nushield, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
99.526 |
- |
- |
- |
- |
- |
- |
|
|
Q4186 - Epifix, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
156.229 |
- |
- |
- |
- |
- |
- |
|
|
Q4195 - Puraply, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
95.485 |
- |
- |
- |
- |
- |
- |
|
|
Q4196 - Puraply am, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
108.758 |
- |
- |
- |
- |
- |
- |
|
|
Q5101 - Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram |
1 MCG |
0.413 |
- |
- |
- |
- |
- |
- |
|
|